Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-22-0301
Abstract: Abstract Purpose: We hypothesized that inhibition and trapping of PARP1 alone would be sufficient to achieve antitumor activity. In particular, we aimed to achieve selectivity over PARP2, which has been shown to play a role… read more here.
Keywords: parpi; inhibitor; generation; parp1 ... See more keywords
Abstract 2730: Preclinical characterization of the anti-PD-L1 monoclonal antibody LY3300054
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-2730
Abstract: Modulating the PD-L1/PD-1 axis in man through function blocking antibodies can release potent anti-tumor immunity, leading to durable objective responses across multiple tumor types. Here we describe the discovery and preclinical characterization of LY3300054, a… read more here.
Keywords: preclinical characterization; antibody; monoclonal antibody; anti monoclonal ... See more keywords
Abstract 4561: Preclinical characterization of GLS-010 (AB122): A fully humanized clinical-stage anti-PD-1 antibody
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-4561
Abstract: INTRODUCTION: Exhausted T cells express high levels of several immune checkpoint proteins, including the programmed death-1 (PD-1) receptor. Preclinical and clinical data support the role of the PD-1/PD-L1 axis in promoting tumor evasion by curtailing… read more here.
Keywords: preclinical characterization; antibody; gls 010; characterization gls ... See more keywords
Abstract 7132: Preclinical characterization of LAE119, a novel PARP1 selective inhibitor and trapper
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-7132
Abstract: Current PARP inhibitors primarily target PARP1/2 and demonstrate high efficacy against tumors with deficiencies in homologous recombination repair, such as those with BRCA mutations. However, these inhibitors are also associated with significant hematological toxicities. Studies… read more here.
Keywords: preclinical characterization; characterization lae119; parp1; lae119 ... See more keywords
Abstract 3004: Preclinical characterization of CGT6297, a novel PI3Kα H1047R mutant-selective inhibitor
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-3004
Abstract: PIK3CA encodes the p110α catalytic subunit of PI3-kinase alpha (PI3Kα) and is the most frequently mutated kinase in human cancer with common mutations occurring in the kinase domain (H1047R) and helical domain (E542K/E545K). The approved… read more here.
Keywords: cancer; preclinical characterization; characterization cgt6297; inhibitor ... See more keywords
Preclinical Characterization of Relatlimab, a Human LAG-3–Blocking Antibody, Alone or in Combination with Nivolumab
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Immunology Research"
DOI: 10.1158/2326-6066.cir-22-0057
Abstract: Novel therapeutic approaches combining immune checkpoint inhibitors are needed to improve clinical outcomes for patients with cancer. Lymphocyte-activation gene 3 (LAG-3) is an immune checkpoint molecule that inhibits T-cell activity and antitumor immune responses, acting… read more here.
Keywords: lag; relatlimab; characterization relatlimab; relatlimab human ... See more keywords
Synthesis and preclinical characterization of novel ruthenium (II) arene complexes for the treatment of solid tumors.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e14512
Abstract: e14512Background: The development of metallopharmaceutics has placed organometallic ruthenium (II) complexes in the spotlight of interest. Although platinum agents are still the main therapeutic op... read more here.
Keywords: ruthenium; characterization novel; synthesis preclinical; preclinical characterization ... See more keywords
Advances in the preclinical characterization of the antimicrobial peptide AS-48
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Microbiology"
DOI: 10.3389/fmicb.2023.1110360
Abstract: Antimicrobial resistance is a natural and inevitable phenomenon that constitutes a severe threat to global public health and economy. Innovative products, active against new targets and with no cross- or co-resistance with existing antibiotic classes,… read more here.
Keywords: antimicrobial peptide; range; action; advances preclinical ... See more keywords
Preclinical Characterization of a Novel Anti-Cancer PD-L1 Inhibitor RPH-120
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2021.723038
Abstract: RPH-120 is a novel fully human anti-PD-L1 IgG1 monoclonal antibody with specifically designed Asn300Ala mutation in Fc fragment. Surface plasmon resonance assay showed that affinity of the RPH-120 to the dimeric form of human PD-L1-Fc… read more here.
Keywords: novel; rph 120; preclinical characterization; anti ... See more keywords